Isomorphic Labs Raises $5 Billion to Push AI-Designed Drugs Toward Clinical Trials

Isomorphic Labs Raises $5 Billion to Push AI-Designed Drugs Toward Clinical Trials

Isomorphic Labs, the AI drug discovery company led by Demis Hassabis, has raised $5 billion in a new Series C funding round. The Isomorphic Labs funding was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and Alphabet putting in significant money again. The company says the cash will help move its first AI-designed medicines toward human trials.

Inside the Isomorphic Labs Funding Round

The London-based company announced the round on November 17, 2026. Greenoaks and Sequoia shared the lead, and a16z came in alongside several other new investors. Every existing backer also took part again.

That list of returning investors is long. It includes Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, plus parent company Alphabet. The company did not share a valuation in its announcement.

DetailWhat We Know
Round size$5 billion (Series C)
Co-leadsGreenoaks and Sequoia Capital
Other new investorsAndreessen Horowitz (a16z) and others
Returning investorsAlphabet, Thrive Capital, MGX, GV, CapitalG, Temasek, UK Sovereign AI Fund
Previous round$2.1 billion Series B
HeadquartersLondon, with offices in Cambridge, Massachusetts and Lausanne

What Isomorphic Labs Actually Builds

Isomorphic was founded in 2021, and Alphabet remains one of its biggest backers. Its core product is an internal system called IsoDDE, short for Isomorphic Drug Design Engine. Think of it as a bundle of AI models that simulate how molecules behave in the body.

The company says IsoDDE can explore huge spaces of possible chemicals and help its scientists design molecules with good drug-like properties. It works across several disease areas and several types of drugs, not just one. Isomorphic also says it uses its own AI agents to reason through complex biology.

Where the Pipeline Stands

According to the company, its work is already producing positive preclinical results. That means lab and animal-stage testing, before any human studies. Its internal programs focus on cancer (oncology) and immune system diseases (immunology), and it runs partnered programs too.

Isomorphic describes these results as “setting the stage for clinical entry.” In plain terms, it has not started human trials yet, but this money is meant to get it there.

How the Money Will Be Used

The company laid out several priorities for the new capital. Here is the short version:

  • Keep improving IsoDDE and build new foundational biology models
  • Study disease biology more deeply, including through a new partner ecosystem
  • Build global computing infrastructure for AI-led bioengineering
  • Set up translational and clinical development systems to run drug trials
  • Move its first therapeutic programs into clinical trials

Founder and CEO Demis Hassabis said the round lets the company drive its “first therapeutic programs towards clinical trials.” President Max Jaderberg added that its models are producing repeatable scientific gains every week.

Why This AI Drug Discovery Bet Matters

A $5 billion round is huge for any startup, and even bigger for one with no approved drugs yet. It shows how much investors now believe AI can shorten the slow, costly path to new medicines. Isomorphic is also not alone in this race.

Other companies are chasing the same goal. Iambic recently went public to fund AI-designed cancer drugs, and AstraZeneca signed a drug discovery deal with insitro. Pathos AI also raised a large round for AI drug development.

Still, funding is not the same as proof. Most drug candidates fail in human trials, whether people or AI designed them. The real test for Isomorphic comes when its molecules face patients.

What This Means for You

You will not find an Isomorphic-designed pill at your pharmacy any time soon. Drugs usually spend years in clinical trials before approval. But this deal still tells you a few useful things.

  • AI is moving from chatbots into hard science like medicine, much like Google’s work on antibiotic discovery
  • Big investors are betting the biggest AI payoffs may come in health care, not just software
  • Watch for news of Isomorphic’s first clinical trial, since that will show whether the approach works in people
  • If you work in pharma or biotech, AI design tools are quickly becoming standard, so it pays to learn them now

For more on how AI is reshaping health and science, browse our research AI tools roundup or the latest updates on our AI news page.

Sources

Primary source: Isomorphic Labs’ Series C announcement.

Conclusion

Isomorphic Labs now has $5 billion more to prove that AI can design real medicines faster than traditional labs. The backing from Sequoia, Greenoaks, a16z and Alphabet shows strong confidence in its IsoDDE engine. The company says its first programs are headed toward clinical trials, which is where the hype meets reality. If those trials go well, this round could mark a turning point for AI in medicine. For now, it is a very expensive and very interesting bet worth watching.

Newsletter

New AI tools in your inbox

The best new tools and the AI news that matters, in one short email. Unsubscribe any time.

Free · No spam · Unsubscribe any time

✓ Looks like you’re subscribed

Loading Google’s sign-up form…

Looks like you’re already subscribed

Thanks for reading! New AI tools and the AI news that matters will land in your inbox.

Not subscribed yet? Refresh the page to load the sign-up form.

The sign-up form couldn’t load. If you use an ad or content blocker, allow news.google.com and reload the page.

Free instant check before you pay. Takes a few seconds.

Scroll to Top